Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Trial Identifier: D933RC00002
Sponsor: AstraZeneca
Start Date: April 2025
Primary Completion Date: October 2028
Study Completion Date: October 2028
Condition: Bladder - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Chermside, AU, 4032
AU Elizabeth Vale, AU, 5112
AU Heidelberg, AU, 3084
AU Kogarah, AU, 2217
AU Macquarie University, AU, 2109
AU Murdoch, AU, 6150
AU Port Macquarie, AU, 2444
AU St Leonards, AU, 2065
BR Barretos, BR, 14784-400
BR Porto Alegre, BR, 91350-200
BR Santo Andre, BR, 09060-650
BR Sao Paulo, BR, 01246-000
CA, ON Hamilton, ON, CA, L8V 5C2
CA, Ontario London, Ontario, CA, N6A 5W9
CA, QC Quebec, QC, CA, G1J 1Z4
CA, QC Sherbrooke, QC, CA, J1H 5N4
ES Barcelona, ES, 8003
ES Barcelona, ES, 08035
ES Barcelona, ES, 08036
ES Barcelona, ES, 08025
ES Gerona, ES, 17007
ES Las Palmas de Gran Canaria, ES, 35016
ES Lugo, ES, 27003
ES Madrid, ES, 28040
ES Madrid, ES, 28033
ES Santiago de Compostela, ES, 15706
FR Angers, FR, 49933
FR Bordeaux Cedex, FR, 33075
FR Chambray-lès-Tours, FR, 37170
FR Dijon, FR, 21079
FR LILLE, FR, 59037
FR Lyon, FR, 69008
FR Marseille, FR, 13009
FR Montpellier, FR, 34070
FR Nice Cedex 2, FR, 06189
FR Nimes, FR, 30029
FR Paris cedex 15, FR, 75900
FR PIERRE BENITE, FR, 69310
FR POITIERS, FR, 86021
FR Quint-Fonsegrives, FR, 31130
FR Rennes, FR, 35000
FR Rouen, FR, 76230
FR Strasbourg, FR, 67033
FR Suresnes, FR, 92150
IT Firenze, IT, 50139
IT Orbassano, IT, 10043
IT Roma, IT, 00144
NL Amsterdam, NL, 1066CX
NL Rotterdam, NL, 3015 GD